WO2004099406A1 - 改変ダニ主要アレルゲンの精製方法 - Google Patents
改変ダニ主要アレルゲンの精製方法 Download PDFInfo
- Publication number
- WO2004099406A1 WO2004099406A1 PCT/JP2004/005315 JP2004005315W WO2004099406A1 WO 2004099406 A1 WO2004099406 A1 WO 2004099406A1 JP 2004005315 W JP2004005315 W JP 2004005315W WO 2004099406 A1 WO2004099406 A1 WO 2004099406A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- modified
- major
- allergen
- mite
- tick
- Prior art date
Links
- 239000013566 allergen Substances 0.000 title claims abstract description 229
- 238000000034 method Methods 0.000 title claims abstract description 66
- 238000000746 purification Methods 0.000 claims abstract description 42
- 210000003000 inclusion body Anatomy 0.000 claims abstract description 33
- 239000012528 membrane Substances 0.000 claims abstract description 27
- 150000001450 anions Chemical class 0.000 claims abstract description 23
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 15
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 13
- 238000010353 genetic engineering Methods 0.000 claims abstract description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 37
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 34
- 108010082995 Dermatophagoides farinae antigen f 2 Proteins 0.000 claims description 31
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 27
- 238000004458 analytical method Methods 0.000 claims description 21
- 239000011780 sodium chloride Substances 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 15
- 239000004202 carbamide Substances 0.000 claims description 14
- 241000588724 Escherichia coli Species 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 13
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 13
- 239000002158 endotoxin Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000005215 recombination Methods 0.000 claims description 10
- 229920000642 polymer Polymers 0.000 claims description 9
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 8
- 241000238876 Acari Species 0.000 claims description 7
- 239000003638 chemical reducing agent Substances 0.000 claims description 7
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 7
- 239000008367 deionised water Substances 0.000 claims description 7
- 229910021641 deionized water Inorganic materials 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000007865 diluting Methods 0.000 claims description 5
- 238000005349 anion exchange Methods 0.000 claims description 4
- 108010061608 Dermatophagoides pteronyssinus antigen p 2 Proteins 0.000 claims description 3
- 238000005406 washing Methods 0.000 abstract description 18
- 238000005516 engineering process Methods 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 45
- 229960004784 allergens Drugs 0.000 description 32
- 239000000872 buffer Substances 0.000 description 29
- 235000002639 sodium chloride Nutrition 0.000 description 29
- 238000011282 treatment Methods 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- 239000007983 Tris buffer Substances 0.000 description 13
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 239000000306 component Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 208000026935 allergic disease Diseases 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 206010020751 Hypersensitivity Diseases 0.000 description 7
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 7
- 229960003067 cystine Drugs 0.000 description 7
- 230000006798 recombination Effects 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 206010002199 Anaphylactic shock Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000007815 allergy Effects 0.000 description 6
- 208000003455 anaphylaxis Diseases 0.000 description 6
- 239000000356 contaminant Substances 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
- 102000016943 Muramidase Human genes 0.000 description 5
- 108010014251 Muramidase Proteins 0.000 description 5
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000004325 lysozyme Substances 0.000 description 5
- 229960000274 lysozyme Drugs 0.000 description 5
- 235000010335 lysozyme Nutrition 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 150000007523 nucleic acids Chemical group 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 238000011067 equilibration Methods 0.000 description 4
- 239000013613 expression plasmid Substances 0.000 description 4
- 238000001155 isoelectric focusing Methods 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical group CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000003398 denaturant Substances 0.000 description 3
- 238000000586 desensitisation Methods 0.000 description 3
- 239000000428 dust Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 238000001641 gel filtration chromatography Methods 0.000 description 3
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- DIWRORZWFLOCLC-UHFFFAOYSA-N Lorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-UHFFFAOYSA-N 0.000 description 2
- 101710175243 Major antigen Proteins 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 108020005091 Replication Origin Proteins 0.000 description 2
- 239000007976 Tris-NaCl-Tween buffer Substances 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000000919 anti-host Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 229960000789 guanidine hydrochloride Drugs 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012533 medium component Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000004271 weak anion exchange chromatography Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 229940074608 allergen extract Drugs 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000003617 indole-3-acetic acid Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000006176 redox buffer Substances 0.000 description 1
- 238000002407 reforming Methods 0.000 description 1
- 238000006057 reforming reaction Methods 0.000 description 1
- 239000012465 retentate Substances 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000002305 strong-anion-exchange chromatography Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- the present invention relates to a method for purifying a modified tick main allergen obtained by genetic recombination technology using E. coli as a host.
- 1 Cleaning and recovery of inclusion bodies containing major allergens with mite using MF membrane 2 Dissolution / refolding of inclusion bodies, 3 Ultrafiltration membrane treatment, 4 Non-adsorption image by anion exchanger treatment High-purity obtained by the purification method of the modified major mite allergens, including the following steps: (5) collection of adsorbed fraction by hydrophobic gel treatment, and (6) collection of adsorbed fraction by anion exchanger treatment The modified tick major allergen.
- Antiallergic agents and antihistamines are often used to treat allergic diseases such as allergic asthma, allergic rhinitis, allergic dermatitis, or allergic conjunctivitis. It is not possible. Desensitization therapy, injecting the causative antigen, is considered the only radical treatment for allergic diseases. Desensitization therapy is a treatment that eliminates allergic reactions in the body by injecting allergic patients in small amounts with the allergen that causes them. The effective rate is said to be over 70%.
- mite allergen product is house dust allergen.
- House duster allergens are produced by a method that extracts allergens from indoor dust.
- mite allergen preparations produced by this method contain various antigens other than mites, such as mold and bacteria, and their biological activity (titer) cannot be clearly defined.
- Another problem is that the raw materials are limited and it is difficult to stably supply a large amount of allergens.
- Allergen preparations are mainly administered subcutaneously for the purpose of inducing immunity. If impurities are mixed in the allergen product, the body may have an immune response to unintended impurities, and sensitization to the impurities may be established. In other words, it may induce new allergies to impurities and cause serious side effects. Therefore, to ensure the safety of allergen preparations, it is necessary to supply highly purified preparations.
- type I allergy represented by anaphylactic shock
- allergen administration always has the potential to cause anaphylactic shock. To do.
- Modified tick major allergens that have disrupted part of the three-dimensional structure of mite allergens and reduced their binding to IgE antibodies by genetic recombination technology.
- modified tick major allergens are a drug that replaces the systemic residue of the major tick allergen Der f 2 with a serine residue, and can be safely desensitized and treat allergies without causing anaphylactic shock. I can expect.
- major mite allergens derived from genetic engineering produced at the industrial production level have been purified to pharmaceutical grade.
- Recombinant tick major allergen Der f 2 transforms prokaryotes or eukaryotes with an expression vector containing the gene encoding Der f 2 and cultures the resulting transformants and purifies them from the culture It is prepared by.
- purification from the culture is performed by ion exchange chromatography and gel filtration chromatography.
- the purity of the major mite allergen Der f 2 thus purified is only reagent grade, and the modified major mite allergen is refolded by dialysis, making it difficult to process in large quantities.
- An object of the present invention is to provide a method for purifying a modified tick major allergen produced by genetic manipulation to a pharmaceutical grade.
- Another object of the present invention is to provide a high-purity modified major mite allergen that is free from contaminating components such as host-derived components, obtained by the purification method of the present invention.
- the inventors of the present invention have conducted extensive research to achieve the above object. As a result, (1) a process of washing and recovering an inclusion body containing a modified major tick allergen obtained by gene manipulation with an MF membrane, (2) the encapsulation Step of refolding after dissolving the body, 3 Concentrating the modified tick major allergen-containing solution with a permeation membrane and removing low molecular components at the same time, 4 Non-modified tick major allergen with a weak anion exchanger By collecting the adsorbed fraction in the adsorbed fraction, 5 collecting the modified main mite allergen in the hydrophobic gel in the adsorbed fraction, and 6 collecting the modified main mite allergen in the adsorbed fraction in the strong anion exchanger, The inventors have found that the modified major mite allergen can be efficiently purified from the culture of the modified tick major allergen producing host, and have completed the present invention.
- the present invention relates to a method for purifying a modified major mite allergen obtained by a gene recombination technique.
- the reforming is performed by diluting or removing the denaturing agent
- the above purification method is characterized by including a purification step of recovering the modified major mite major allergen in the adsorbed fraction by eluting with a change.
- the present invention further relates to a purified modified major mite allergen obtained by the above purification method.
- the present invention relates to a modified mite major allergen obtained by gene recombination technology in which the cysteine residues at positions 8 and 1 19 of mite major allergen Der f 2 are substituted with serine residues.
- the major allergen Der f 2 has a molecular weight of about 15 kD and an isoelectric point of PI 6.6-7.2 obtained by the purification method described above,
- the content of impure protein derived from the host is 1% or less
- the polymer content of the modified major mite allergen is 10% or less
- the content of major mite allergens with different steric structures is 10% or less, (5) The endotoxin content of the 500 g / ml modified tick major allergen solution is
- the polymer content of the modified major mite allergen is 0.005 to 10%.
- the main allergen content of mites with different steric structures is 0.03-10%
- the endotoxin content of the 500 g / tnl modified tick major allergen solution is 0.002 to 0.25 EU / ml.
- composition mainly comprising the modified major mite allergen Der f 2 and the modified major mite major allergen.
- the modified major mite allergen obtained by genetic manipulation can be purified efficiently and in large quantities, so it is suitable for industrial production of three female tick major allergens and is stable.
- a single modified tick major allergen formulation can then be supplied.
- the purity of the target major mite allergen can be effectively increased by carrying out a purification step using a strong anion exchanger ram in the presence of urea.
- the modified major mite allergen Der f 2 is obtained by substituting the cysteine residues at positions 8 and 1 19 of mite major allergen Der f 2 with serine residues.
- the modified major mite allergen is different from the native mite major allergen, and part of the three-dimensional structure is destroyed to reduce the binding to IgE antibody.
- the modified double major allergen is (1) a single band by SDS-PAGE analysis, (2) the amount of impure protein derived from the host is 0.1% or less, and (3) a modified tick.
- Polymer content of major allergens is below detection limit, (4) Modified mite major allergen content with different steric structure is less than 10%, (5) 500 ⁇ g / ml modified major mite allergen endotoxin A high-purity modified major mite allergen with a content of less than 0.25 EU / ml (the 14th revision Japanese Pharmacopoeia), which is the standard for water for injection, is provided. That is, according to the method of the present invention, contaminants derived from the host can be substantially removed, and serious side effects on the contaminants can be avoided, so that a safe modified major mite allergen preparation is provided. Is done.
- FIG. 1 shows the construction method of the expression vector pWUll-C8 / 119S.
- Figure 2 shows the growth curve of cells during fermenter culture.
- Figure 3 shows the results of recombinant Escherichia coli grown in fermenter culture, sampled over time, sonicated, and subjected to SDS-polyacrylamide gel electrophoresis.
- Lane 1 Before 37 ° C temperature shift, Lane 2: 37 ° C temperature shift after 1 hour, Lane 3: Temperature shift after 3 hours, Lane 4: Temperature shift after 5 hours, Lane 5: Temperature shift after 7 hours Lane 6: Temperature shift 9 hours later Lane 7: Temperature shift 12 hours later.
- Figure 4 shows the results of a Western plot using an anti-Der f 2 monoclonal antibody.
- Lane 1 Non-reducing treatment of the purified modified tick major allergen.
- Lane 2 Reduction treatment of the purified modified tick major allergen.
- Figure 5 shows the results of SDS-polyacrylamide gel electrophoresis for the purity of the modified major mite allergen at each purification step.
- Lane 1 Refolding
- Lane 2 Weak anion exchange chromatography
- Lane 3 Purified modified tick major allergen.
- FIG. 6 shows the results of subjecting purified modified mite major allergen to SDS-polyacrylamide gel electrophoresis. Lane 1: Non-reducing treatment of purified modified tick major allergen, Lane 2: Reduction treatment of purified modified tick major allergen.
- Figure 7 shows the matrix pattern obtained by gel filtration HPLC analysis of the purified modified tick major allergen.
- Figure 8 shows the chromatograms obtained by reverse phase HPLC analysis of the purified major mite major allergen.
- Figure 9 shows the results of subjecting purified major mite major allergens (3 lots) to isoelectric focusing.
- Lane 1 SF-01
- Lane 2 FP-020
- Lane 3 FP-021.
- Fig. 10 shows the refined product Der f 2 (Asahi Beer) and the refined modified product of the present invention. The results of subjecting two major allergens to polyacrylamide gel electrophoresis are shown. Lane 1: Der f 2, Lane 2: Modified tick major allergen FP-020, Lane 3: Modified tick major allenogen FP-021.
- the purification method of the present invention includes: (1) a step of washing and recovering a modified mite major allergen-containing inclusion body obtained by genetic manipulation, (2) a step of dissolving and refolding the inclusion body, and (3) a liquid containing a modified tick major allergen. Concentrate the sucrose with an ultrafiltration membrane and remove low-molecular components at the same time, 4 Collect the modified major mite allergen with an anion exchanger in the non-adsorbed fraction, 5 Adsorb the modified major mite allergen with a hydrophobic gel And (6) a step of recovering the major allergen of modified mite into an adsorbed fraction using an anion exchanger.
- Modified major mite allergens obtained by gene recombination that are the subject of the purification method of the present invention are those prepared using major mite allergen genes such as Der f 2 and Der p 2 identified so far. Is mentioned.
- the total amino acid sequence of each major tick allergen Der f 2 and Der p 2 (Chua KY, Int. Arch. Allergy Appl. Immunol. 91 (2), 118-123 (1990)) is over 80% In both cases, the position of S—S bond is the same. Therefore, a modified mite major allergen can be obtained by partially mutating the base sequence of any nucleic acid fragment containing any gene of these major mite allergens.
- modified major mite allergen examples include, for example, the 8th and 1 1 9th positions of the major mite allergen Der f 2 described in JP-A-6-2 5 3 8 5 1.
- Der f 2 is a major mite allergen in which both cysteine residues are replaced with serine residues.
- the three-dimensional structure of the major mite allergen was modified to reduce the binding to IgE antibodies.
- Other modified tick major allergens can also be used.
- the major mite allergen gene a modified mite major allergen gene in which a part of the base sequence was replaced, is derived from mRA extracted from mites or genomic DNA. It can be prepared according to a general gene recombination technique described by Sambrook et al. (Molecular Cloning, A Laboratory Manual Second Edition. Cold Spring Harbor Laooratory Press, NY, 1989).
- RNA extraction RNA extraction, TRIzol reagent (Invitrogen), IS0GEN (Nitsubon Gene), StrataPrep Total RNA
- reagents such as Purification Kit (Toyobo), mRNA, raRNA Purification Kit (Amersham Biosciences), Poly (A) Quick mRNA Isolation Kit
- the modified tick major allergen gene is prepared by preparing a plasmid carrying the modified tick major allergen cDNA according to the method described in Japanese Patent Application Laid-Open No. Hei 6-25 385. It can be obtained by performing PCR as a saddle type.
- a modified major tick allergen can be produced by introducing such a modified major tick allergen gene into an appropriate host.
- a host include animal cells, plant cells, insect cells, or microorganisms such as E. coli, yeast, Bacillus subtilis. It can also be produced by large and small animals called animal factories.
- the modified tick major allergen-containing material used in the present invention is not particularly limited as long as it is prepared through genetic manipulation, and has already been disclosed in the literature, etc., and will be developed in the future However, it can be used as appropriate.
- a culture of a host producing the above-mentioned major mite major allergen or a body fluid or secretion of a recombinant large or small animal can be mentioned.
- it is a culture of modified tick major allergen-producing Escherichia coli.
- the expression induction is performed by a method that does not use an expression inducer such as indoleacetic acid (IM) or isopropylthio-beta-1D-galactoside (IPTG).
- an expression inducer such as indoleacetic acid (IM) or isopropylthio-beta-1D-galactoside (IPTG).
- IM indoleacetic acid
- IPTG isopropylthio-beta-1D-galactoside
- Cultures of E. coli major allergen producing E. coli are used.
- Such a modified mite major allergen-containing culture containing no expression inducer can be obtained by, for example, the method described in Japanese Patent Application No. 2003-058 992.
- the modified tick major allergen gene is incorporated into an expression plasmid composed of a tributofan promoter and a pUC-derived replication origin, and E. coli is transformed with the expression plasmid to express the modified tick major allergen.
- E. coli is transformed with the expression plasmid to express the modified tick major allergen.
- the glycerin stock is used as an inoculum to perform two-stage culture. First, low-temperature (25 0 C ⁇ 32 ° C) with sufficiently cultured grown cells, and cause expression of the modified major mite allergen by then shifting the culture temperature to a high temperature (37 ° C ⁇ 38 ° C) . By performing such two-stage culture, a modified darning major allergen-containing culture containing no expression inducer can be obtained.
- the culture period depends on the culture temperature and the production scale of the major mite allergen, but the low temperature culture is performed until the recombinant Escherichia coli reaches the middle of the logarithmic growth phase. High temperature culture is performed until the amount of the major mite allergen reaches a peak.
- 10 ml of the glycerin stock of the recombinant E. coli (pWUll-C8 / 119S / HB101) obtained in Example 1 was inoculated into about 1 L of medium and cultured at 32 ° C for 6 to 10 hours. Inoculate ⁇ 300L of medium and incubate at 25 ° C for 12-17 hours. Thereafter, by culturing at 37 ° C. for 8 to 16 hours, inclusion bodies composed of the modified main mite allergen are produced in a wet weight of about 7 to 10 g / L.
- the culture solution is concentrated using an MF membrane (manufactured by Asahi Kasei Co., Ltd.) to recover the cells.
- the size of the MF membrane used here is preferably 0.1 to 0.25 1! 1.
- the collected cells are crushed by an appropriate method, and the inclusion bodies composed of the modified major mite allergen are released outside the cells.
- a method of dissolving with a chemical substance, a surfactant, an enzyme, or the like, or a method of physical treatment such as French press or ultrasonic treatment is used, and any method may be used. By combining these methods several times, the cells can be more effectively disrupted.
- the bacterial cells recovered by the MF membrane are diluted and concentrated with deionized water to remove the remaining medium components and bacterial metabolites, and then use an appropriate buffer and retentate. Add zoteam and let stand at low temperature (4 ⁇ 15 ° C) to dissolve the cell wall of the cells, and then apply this cell processing solution to the French press (Manton Gorin Co., Ltd.) at 500-600kg m 2 ) To crush the cells.
- the type of buffer solution is not particularly limited as long as it has a buffer capacity in the pH range (7.5 to 9) where lysozyme acts, such as Tris buffer solution.
- the concentration of the buffer solution may be used within a range generally used as a buffer solution (10 to 50 raM).
- Lysozyme is used at a concentration of 0.3 to 1.0 g / L.
- addition of P H8. 5 Tris buffer of 20RaM was added lysozyme (0. 6g / L), and 4 ° C De ⁇ location dissolving cell walls of the bacteria.
- the cells are broken with a French press, most of the cell components are removed by repeating dilution and concentration of the broken solution with deionized water and MF membrane. Inclusion bodies are collected as precipitates by centrifuging the concentrated inclusion body-containing solution.
- the collected inclusion bodies are dissolved in a solution containing a reducing agent and a denaturing agent.
- a reducing agent cystine, dartathione, dithiothreitol, 2-mercaptoethanol and the like can be used. These may be used in combination.
- the concentration of the reducing agent depends on the amount of inclusion bodies to be dissolved, but is used in the range of 10 to lOOraM. Preferably, it is the range of 10-50raM.
- Urea, guanidine hydrochloride and the like can be used as the denaturing agent, but urea is preferred. Strong urea and guanidine hydrochloride are used in concentration ranges of 4-8M and 2-6M, respectively.
- a buffer solution having a pH of 7 to ll is used.
- the pH is 8-9.
- any of phosphate buffer, tris buffer, glycine buffer, carbonate buffer and the like having buffering ability in the above pH range may be used.
- the inclusion body is recovered.
- a buffer similar to that described is used. More specifically, inclusion bodies are dissolved in Tris buffer at pH 8.5 containing 20 mM cysteine and 8 M urea.
- the temperature at the time of dissolution is not particularly limited as long as it is 40 ° C or less. The dissolution time may be set while observing the dissolution state of the inclusion body, and is usually stirred for 30 minutes to 1 hour.
- the ss bond is reconstituted under normal conditions.
- Cysteine is used as the reducing agent and cystine is used as the oxidizing agent.
- Cystine and cystine are used in concentration ranges of 1 raM to 10 mM and 0.1 lmM to 1 mM, respectively. It is preferred to use 1/10 amount of cystine relative to cysteine.
- the type and concentration of the buffer used for refolding should be the same as those used to dissolve the inclusion bodies.
- the pH of the buffer is used in the range of 7.5-9. More specifically, refolding is accomplished by diluting or removing the denaturant using 20 mM Tris buffer, pH 8.5, containing 3 raM cysteine and 0.3 mM cystine. When removing the denaturant, dialysis, gel filtration, etc. are used.
- the temperature during refolding need not be limited as long as it is below room temperature. Refolding is performed by allowing to stand for 1 to 7 days, preferably 3 to 4 days.
- the refolding reaction is terminated by adding an acidic buffer such as acetic acid or hydrochloric acid to neutralize the pH of the reaction solution. More specifically, the reaction is stopped by titrating the reforming reaction solution with 30% acetic acid to ⁇ 7.
- an acidic buffer such as acetic acid or hydrochloric acid
- the modified mite major allergen-containing solution after the refolding treatment is subjected to ultrafiltration membrane treatment with a molecular weight cut off of 600 to 10,000 for concentration and removal of low-molecular components.
- the pH is adjusted to 8 to 9 with an alkaline solution.
- the precipitate generated at this time is removed with a filter of ⁇ 0.45 / ⁇ .
- sodium chloride is added to a final concentration of 50 mM, and the pH is adjusted to 8.5 with a 5N aqueous sodium hydroxide solution.
- the ultrafiltration treatment is performed at room temperature or lower.
- the modified tick major allergen-containing solution is subjected to the next purification step.
- the solution containing the modified major mite allergen after ultrafiltration is passed through the anion exchanger ram and the modified major mite allergen is collected in the flow-through fraction.
- the operation is performed at 5-10 ° C.
- the anion exchanger include a jetylaminoethyl (DEAE) group type, a quaternary aminoethyl (QAE) group type, and the like.
- DEAE-based types include DEAE—agarose (trade name DEAE—Sepharose, manufactured by Amersham), DEAE—dextran (product) Name DEAE—Cef Adex, manufactured by Amersham), DEAE-Polybule (trade name DEAE—Toyopearl, manufactured by Tosoh Corporation), and the like.
- the QAE base type examples include QAE-agarose (trade name QAE-Sepharose, manufactured by Amersham), QAE-polybule (trade name QAE-Toyopearl, manufactured by Tosoh Corporation), and the like.
- the support is not particularly limited, but a weak anion exchanger is preferably used as the functional group.
- Buffer type particularly limited, such bur for use in the anion exchange, P H when contacting the modified major mite allergen to the column in the range of 7-10, preferably pH8 ⁇ 9 use .
- the salt concentration is a force that can be used in the range of 0.03 M to 0.1 M, preferably 30 to 60 raM. This purification process removes most of the impure protein.
- the flow-through fraction of the anion exchanger is buffer-exchanged with a buffer containing sodium chloride, and then contacted with a hydrophobic column equilibrated with the buffer to adsorb the modified major mite allergen.
- concentration of the sodium chloride is used in the range of 2 to 3M, preferably 3M.
- concentration in the range of 5 ⁇ 50raM, preferably in the range of 10 ⁇ 20raM, P H is used in the range of 7-8.
- the hydrophobic gel include a phenyl group type, a butyl group type, and an octyl group type.
- the support examples include agarose (manufactured by Amersham), dextran (manufactured by Amersham), polybule (manufactured by Tosoh Corporation), and the like. Although there is no particular limitation on the support in this purification step, it is preferable to use a butyl group type functional group.
- the modified major mite allergen is eluted from the hydrophobic column by reducing the salt concentration.
- the method for lowering the salt concentration include a method using a concentration gradient and a method of stepwise decreasing the salt concentration (stepwise). Any method may be used.
- substances that change the salt concentration include ammonium sulfate, ammonium acetate, ammonium chloride, ammonium nitrate, potassium acetate, sodium chloride, sodium acetate, calcium chloride, magnesium chloride, etc. However, either can be used. In the present invention, a stepwise method is used.
- the salt concentration at elution is 0 to 1M, preferably 0M.
- a series of column operations in hydrophobic chromatography is performed at 5-10 ° C. (vi) Recovery of adsorbed fraction by anion exchanger treatment
- the elution fraction of the hydrophobic ram is exchanged with a buffer containing urea, and then contacted with an anion exchange ram that has been equilibrated with the buffer to adsorb the modified major mite allergen. Aggregation of the modified major mite allergen can be suppressed by containing urea in the buffer.
- the urea concentration is a force used in the range of 0.5 to 5M, preferably 1 to 3M.
- the type of buffer is not particularly limited, but the concentration is in the range of 5 to 50 mM, preferably in the range of 10 to 20 raM, the pH is in the range of 8 to 10, preferably 8.5 to 9.5. Used in range. Although there are no particular limitations on the support in this purification step, it is preferable to use a strong anion exchanger as the functional group.
- the modified tick major allergen is eluted from the anion exchanger ram by increasing the salt concentration.
- a method of increasing the salt concentration there are a method using a concentration gradient and a method of increasing the salt concentration stepwise (stepwise), and any method may be used.
- substances that change the salt concentration include sodium chloride, potassium chloride, calcium chloride, and magnesium chloride, and any of them can be used.
- a concentration gradient method is used, which is prepared by dissolving sodium chloride in the same buffer used to equilibrate the column.
- the salt concentration gradient at the time of elution is 0 to 0.5 M, preferably 0 to 0.1 M.
- a series of column operations in anion exchanger treatment is performed at 5 to 10 ° C.
- the eluate containing the modified major mite allergen is dialyzed against PBS and then sterile-filtered through a 0.22 mm filter and stored as a modified tick major allergen.
- the properties of the modified major mite allergens at each purification step and after purification are generally determined by methods used for protein analysis, such as EIA and Western plots using specific antibodies, SDS-polyacrylamide electrophoresis in reduced and non-reduced states ( SDS-PAGE), high-speed liquid chromatography (HPLC), endotoxin test, absorbance measurement, isoelectric focusing, etc.
- the purified modified major mite allergen obtained by the purification method of the present invention is a major tick allergen as a modified major mite allergen obtained by gene recombination technology.
- the modified allergen major allergen Der f 2 in which the cysteine residues at positions 8 and 1 1 9 of Der f 2 are both replaced with serine residues.
- Der f 2 the isoelectric point P I6. 6 -7. It has the characteristics of (2) and (1) SDS-PAGE analysis, single band, (2) host-derived impurity protein content is less than 0.1%, (3) polymer content of major mite allergen Is below the detection limit, (4) The content of major mites / gens with different three-dimensional structures is less than 10%,
- the obtained purified modified tick major allergen is formulated by adding commonly used additives such as stabilizers, surfactants, buffers, etc., followed by aseptic filtration, dispensing, lyophilization, etc.
- the modified major mite allergen preparations prepared in this way can be administered as injections or transmucosally (nasally, orally, sublingually), as well as mite allergen extracts and house dust extracts, as well as therapeutic agents for allergic diseases. It can be used as a clinical preparation for the purpose.
- the cysteine residues at positions 8 and 1 1 and 9 of the major allergen Der f 2 were substituted with serine residues as the major female allergens of the third female tick obtained by genetic recombination technology.
- the modified mite major allergen is purified using the modified mite major allergen Der f 2, but the present invention is not limited to these Examples.
- Example 1 Production of modified major mite allergen-producing recombinant Escherichia coli
- the modified tick major allergen downstream of the Trp promoter (modified tick major allergen Der f 2 in which the cysteine residues at positions 8 and 1 1 and 9 of Dae major allergen Der f 2 are both substituted with serine residues) gene fragment A gene fragment linked with (C8 / 119S) was constructed as follows.
- Trp promoter A gene fragment containing the Trp promoter is described in Ikehara et al. (Proc. Natl. Acad. Sci.
- tryptophan promoter gene fragment is EcoRI linker (TaKaRa) at the 5 and 3 ends. After binding the Company, Ltd.), and ⁇ into the EcoRI site of P BR322, it was to prepare a recombinant vector pW.
- a nucleic acid fragment containing the modified major allergen gene (C8 / 119S) is converted into a plasmid pFLTll-C8 / 119S carrying the modified major mite allergen gene (Japanese Patent Laid-Open No. 6-2 5 3 8 5 1).
- Synthetic primer containing the restriction enzyme cleavage site NspV at the end (SEQ ID NO: 1 in the sequence listing) and 3, Synthetic primer containing the restriction enzyme cleavage site Nrul at the end (SEQ ID NO: 2 in the sequence listing) ) was used to perform PCR.
- the replication start point derived from pBR322 contained in pWll_C8 / 119S was replaced with the replication start point derived from PUC18.
- Plasmid pUC18 was completely digested with restriction enzymes Pvul and PvuII to obtain a gene fragment containing the replication origin.
- the plasmid pWll-C8 / 119S was completely digested with Ndel, the sticky ends were filled, and then completely digested with Pvul to obtain a nucleic acid fragment containing the modified tick major allergen gene (C8 / 119S).
- the two prepared nucleic acid fragments were ligated with T4 ligase to obtain the expression plasmid pWUll_C8 / 119S (FIG. 1).
- Escherichia coli HB101 was transformed with the obtained expression plasmid pWUll-C8 / 119S to obtain a modified tick major allergen expression strain pWUll-C8 / 119S / HB101, which was used as a production strain to prepare a glycerin stock.
- Lysozyme treatment At night, the cells were crushed by applying a French press (manton gorlin) until there was no stickiness. Since heat was generated during crushing, the treatment liquid was cooled to 18 ° C or lower using heat exchange m3 ⁇ 4. The cell disruption solution was diluted 3 times with deionized water to remove cell components and then concentrated to 100 L with an MF membrane 3 times. The concentrated inclusion body solution was centrifuged at 3000 rpm for 3 hours to precipitate and recover the inclusion bodies. The amount of inclusion bodies recovered was 2.5 kg when wet weight was measured.
- the solution is titrated to P H7 with 30% acetic acid, the reaction was stopped.
- This solution was concentrated to about 10 L using an ultrafiltration membrane (manufactured by Zanoretrius) having a molecular weight cut off of 10,000.
- Sodium chloride was added to the concentrated solution so that the final concentration was 50 raM.
- the solution was titrated to pH 8.5 using 5N aqueous sodium hydroxide solution. Insoluble substances and the like were removed with a ⁇ 0.45 / in filter (manufactured by Sartorius) to prepare a refolding solution.
- the Western plot method was used for detection of the modified major mite alloregen.
- the sample was diluted to an appropriate concentration with water for injection, reduced in non-reduced state and 2-mercaptoethanol, added to SDS-polyacrylamide gel (Funakoshi), and electrophoresed.
- This electrophoresis gel was immersed in a transfer buffer (lOmMCAPS containing 10% methanol) for 5 minutes, and then the protein of the electrophoresis gel was transferred to a PVDF membrane using a transestane transfer transfer device.
- the PVDF membrane after the transfer was immersed in lOraM Tris buffer containing 2% sushi serum alpmin, 0.1% Tween20 and 0.5M sodium chloride, and blocked at 37 ° C for 2 hours.
- Te 5 mu g / ml anti Der f 2 monochrome one monoclonal antibody of the Was added and reacted at 37 ° C for 2 hours.
- TNT buffer solution lOraM Tris buffer solution
- the HRP-labeled anti-mouse IgG antibody solution diluted 20000 times was added. The mixture was added and reacted at 37 ° C for 2 hours.
- 0.05% DAB solution was added and color reaction was performed to detect the modified double major allergen (Fig. 4).
- PBS containing Tween20 (hereinafter abbreviated as “PBST”) three times in total
- PBS containing 1% ushi serum albumin was added 200 ⁇ l at a time and subjected to proking at 37 ° C for 1 hour.
- the standard solution and sample solution were appropriately diluted to the plate, added 100 by 1 and allowed to stand at 37 ° C for 2 hours.
- rabbit anti-C8 / 119 S polyclonal antibody diluted 2000-fold was added in ⁇ portions and allowed to stand at 37 ° C for 1 hour.
- An ELISA plate (manufactured by Nunc) was coated with 10 ⁇ g / tnl of a guinea pig anti-host contaminant component polyclonal antibody at 4 ° C. for one coat. 0. 0 5 ° /. After washing 3 times with PBS containing Tween20 (PBST) in total, 200 / ii of Plock Ace (manufactured by Dainippon Reagent Co., Ltd.) was added and blocked at 37 ° C for 1 hour. After washing 3 times with PBST, this plate The sample solution of the modified major mite allergen in the final purification step was appropriately diluted and added in increments of 100 ⁇ 1 and allowed to stand at 37 ° C for 2 hours.
- PBST PBS containing Tween20
- the plate was washed a total of 3 times with PBST.
- 1 ⁇ g / ml of rabbit anti-host-derived contaminant component polyclonal antibody was added 100 / z at a time and allowed to stand at 37 ° C. for 1 hour.
- 100 ⁇ l of rabbit rust peroxidase-labeled donkey anti-rabbit IgG antibody was added and allowed to stand at 37 ° C. for 1 hour.
- TMB solution manufactured by Sigma
- the content of host-derived protein is shown in Table 2. The detection limit of this ELISA system was 0.004%.
- the analysis of the impure protein contained in the modified tick major allergen was performed by reducing the sample of each purification step with 2 -mercaptoethanol and adding 2 zg equivalent of the modified tick major allergen protein per lane to the SDS-poly It was added to an acrylamide gel (manufactured by Funakoshi), electrophoresed, and stained with Coomassie Brilliant Pull. The electrophoresis conditions were in accordance with the manufacturer's attachment. As the purification process progressed, it was confirmed that there were fewer impure protein bands (Fig. 5).
- the purity of the modified major mite allergen in the final purification step was measured by HPLC.
- the polymer content of the modified major mite allergen was measured by gel filtration chromatography, and the modified tick major allergen content resulting from the cross-linking of SS bonds, etc., was determined by reversed phase chromatography.
- the analytical column used was G3000SW XL (manufactured by Tosoh Corporation).
- the mobile phase contains 0.1% TFA.
- a 60% acetonitrile solution was used.
- the flow rate was lml / min and the analysis time was 20 minutes.
- the sample amount was analyzed by adding ⁇ of a sample of about 500 / xg / ml. Since the solvent-derived peak was detected after 12 minutes of analysis, the analysis time was set to I 2 minutes, and the polymer content ratio was calculated from the integrated value for 12 minutes.
- the polymer content of the modified major mite allergen was below the detection limit (Fig. 7).
- the detection limit of this gel filtration chromatography was 0.005%.
- CAPCELL PAK C1 (manufactured by Shiseido Co., Ltd.) was used as the analytical column.
- As the mobile phase a 70% acetonitrile solution containing 0.1% TFA in buffer A and 0.1% TFA in buffer B was used.
- the analysis conditions were a linear gradient with a flow rate of 1 ml / min and a B buffer mixing ratio that varied from 28.6% to 50% in 60 minutes.
- the sample amount was analyzed by adding ⁇ of a sample of about 500 / x g / ral. Since noise was detected immediately after the start of analysis, the analysis time was 13 to 60 minutes, and the main peak content ratio was calculated from the integrated value.
- the content ratio of the target major mite allergen was 90% or more, that is, the content of major mite allergens with different steric structures was 10% or less (Fig. 8).
- the detection limit of this reverse phase chromatography was 0.03%.
- the endotoxin content of (500 mg / ml) was of a quality that met the standard for water for injection of less than 0.25 EU / ml (14th revised Japanese Pharmacopoeia). The limit of detection for this endotoxin test was 0.002 EU / ml.
- Modified main mite allergen (Lot No .: SF-01, FP-020, FP-021) in final purification process Dilute to 15 ( ⁇ g / ml) with water for injection. Was used for isoelectric focusing. Electrophoresis was performed according to the attached manual, and the gel after electrophoresis was stained with silver. As a result, the isoelectric point of the purified modified mite major allergen was estimated to be pI 6.6 to 7.2 (Fig. 9).
- Dilute major mite allergens (Lot No .: FP-020, FP-021) in the final purification process and purified Der f 2 (Asahi Breweries) of conventional products to 200 ⁇ g / mL with physiological saline, per lane 1 ⁇ g was added and subjected to SDS-polyacrylamide gel electrophoresis.
- the electrophoresed gel was stained using a silver staining kit (Daiichi Kagaku) (Fig. 10).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Insects & Arthropods (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Compounds Of Unknown Constitution (AREA)
- Laminated Bodies (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04727416A EP1621615B1 (en) | 2003-05-07 | 2004-04-14 | Method of purifying modified acarian main allergen |
US10/555,883 US7667009B2 (en) | 2003-05-07 | 2004-04-14 | Method for purifying modified major mite allergen |
AT04727416T ATE461278T1 (de) | 2003-05-07 | 2004-04-14 | Verfahren zur reinigung des modifizierten hauptallergens von milben |
DE602004026048T DE602004026048D1 (de) | 2003-05-07 | 2004-04-14 | Verfahren zur reinigung des modifizierten hauptallergens von milben |
JP2005505971A JP4573772B2 (ja) | 2003-05-07 | 2004-04-14 | 改変ダニ主要アレルゲンの精製方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003128610 | 2003-05-07 | ||
JP2003-128610 | 2003-05-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004099406A1 true WO2004099406A1 (ja) | 2004-11-18 |
Family
ID=33432048
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/005315 WO2004099406A1 (ja) | 2003-05-07 | 2004-04-14 | 改変ダニ主要アレルゲンの精製方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US7667009B2 (ja) |
EP (1) | EP1621615B1 (ja) |
JP (1) | JP4573772B2 (ja) |
AT (1) | ATE461278T1 (ja) |
DE (1) | DE602004026048D1 (ja) |
WO (1) | WO2004099406A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016193929A (ja) * | 2010-06-03 | 2016-11-17 | アルク−アベッロ エイ/エスAlk−Abello A/S | ダニアレルゲン抽出物を含んでなる医薬品及びその製造方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA034692B1 (ru) | 2014-03-31 | 2020-03-06 | Бёрингер Ингельхайм Ветмедика Гмбх | Улучшенные транспортные молекулы модулярного антигена и их применение |
AU2016333474A1 (en) | 2015-09-30 | 2018-03-22 | Boehringer Ingelheim Vetmedica Gmbh | Improved modular antigen transportation molecules and uses therof in animals |
CN105769775A (zh) * | 2016-03-24 | 2016-07-20 | 浙江华海药业股份有限公司 | 一种注射用阿扎胞苷的制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06253851A (ja) | 1993-03-04 | 1994-09-13 | Asahi Breweries Ltd | 改変したダニ主要アレルゲン及びその製造方法 |
WO1996030539A1 (fr) * | 1995-03-28 | 1996-10-03 | Asahi Breweries, Ltd. | Allergene d'acarien obtenu grace au genie genetique et son procede de fabrication |
JP2001231563A (ja) * | 2000-02-18 | 2001-08-28 | Asahi Breweries Ltd | 改変したダニアレルゲン(システイン変異体)及びその製造方法 |
JP2001231562A (ja) * | 2000-02-18 | 2001-08-28 | Asahi Breweries Ltd | 改変したダニアレルゲン(プロリン変異体)及びその製造方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5912327A (en) * | 1996-09-30 | 1999-06-15 | Human Genome Sciences, Inc. | Method of purifying chemokines from inclusion bodies |
US6632425B1 (en) * | 1997-03-20 | 2003-10-14 | Human Genome Sciences, Inc. | Chemokine compositions |
IT1318691B1 (it) * | 2000-09-12 | 2003-08-27 | Consiglio Nazionale Ricerche | Varianti di proteine allergeniche del gruppo 2 di dermatophagoides. |
-
2004
- 2004-04-14 JP JP2005505971A patent/JP4573772B2/ja not_active Expired - Fee Related
- 2004-04-14 US US10/555,883 patent/US7667009B2/en not_active Expired - Fee Related
- 2004-04-14 EP EP04727416A patent/EP1621615B1/en not_active Expired - Lifetime
- 2004-04-14 AT AT04727416T patent/ATE461278T1/de not_active IP Right Cessation
- 2004-04-14 DE DE602004026048T patent/DE602004026048D1/de not_active Expired - Lifetime
- 2004-04-14 WO PCT/JP2004/005315 patent/WO2004099406A1/ja active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06253851A (ja) | 1993-03-04 | 1994-09-13 | Asahi Breweries Ltd | 改変したダニ主要アレルゲン及びその製造方法 |
WO1996030539A1 (fr) * | 1995-03-28 | 1996-10-03 | Asahi Breweries, Ltd. | Allergene d'acarien obtenu grace au genie genetique et son procede de fabrication |
JP2001231563A (ja) * | 2000-02-18 | 2001-08-28 | Asahi Breweries Ltd | 改変したダニアレルゲン(システイン変異体)及びその製造方法 |
JP2001231562A (ja) * | 2000-02-18 | 2001-08-28 | Asahi Breweries Ltd | 改変したダニアレルゲン(プロリン変異体)及びその製造方法 |
Non-Patent Citations (4)
Title |
---|
KIN'ICHIRO MIURA ET AL.: "Tanpakushitsu kogaku", 15 July 1988, pages: 118, XP002984698 * |
See also references of EP1621615A4 |
TAKAI ET AL., NATURE BIOTECHNOLOGY, vol. 15, 1997, pages 754 - 758 |
THE JAPANESE BIOCHEMICAL SOCIETY: "Shin seikagaku jikken koza 1 tanpakushitsu I -Bunri.seisei.seishitsu-", 26 February 1990, pages: 169-177, - 184-194, XP002984697 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016193929A (ja) * | 2010-06-03 | 2016-11-17 | アルク−アベッロ エイ/エスAlk−Abello A/S | ダニアレルゲン抽出物を含んでなる医薬品及びその製造方法 |
Also Published As
Publication number | Publication date |
---|---|
US7667009B2 (en) | 2010-02-23 |
ATE461278T1 (de) | 2010-04-15 |
JPWO2004099406A1 (ja) | 2006-07-13 |
US20080113424A1 (en) | 2008-05-15 |
EP1621615A1 (en) | 2006-02-01 |
JP4573772B2 (ja) | 2010-11-04 |
EP1621615A4 (en) | 2007-05-02 |
DE602004026048D1 (de) | 2010-04-29 |
EP1621615B1 (en) | 2010-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chua et al. | IgE binding studies with large peptides expressed from Der p II cDNA constructs | |
Wilson et al. | Removal of tightly bound endotoxin from biological products | |
JPS62223197A (ja) | アルフア−1−抗プロテア−ゼ精製 | |
JP2596466B2 (ja) | ダニの主要アレルゲンの還伝情報を有するdnaおよび該アレルゲンの製造方法 | |
JP5033177B2 (ja) | 陽イオン界面活性剤によるタンパク質の精製 | |
JP5443175B2 (ja) | 疎水性タンパク質を精製する方法 | |
JPS6143991A (ja) | B型肝炎ウイルス表面抗原およびその製造法 | |
US4902783A (en) | Method for purifying a gene-expression product produced by recombinant DNA technique | |
CN117280026A (zh) | 免疫球蛋白切割酶 | |
JPH0545600B2 (ja) | ||
Marquardt et al. | Human glomerular basement membrane. Selective solubilization with chaotropes and chemical and immunologic characterization of its components | |
Bettadapura et al. | Expression, purification, and encephalitogenicity of recombinant human myelin oligodendrocyte glycoprotein | |
Wang et al. | Cloning, expression, and refolding of a secretory protein ESAT-6 of Mycobacterium tuberculosis | |
JP3316535B2 (ja) | ダニアレルゲンの改変体およびその製造法 | |
JPH07188291A (ja) | 蛋白質とその製造方法並びに用途 | |
JP2009521910A (ja) | BetulaVerrucosa花粉の主要アレルゲンの低アレルギー性変種 | |
JP2006014726A (ja) | イエダニ由来のアレルゲン | |
WO2004099406A1 (ja) | 改変ダニ主要アレルゲンの精製方法 | |
CN112358536A (zh) | 拟穴青蟹致敏蛋白Scy p 1衍生物及其应用 | |
JP5868587B2 (ja) | オオアワガエリからの主要アレルゲンPhlp1の変異体 | |
JPH0446559B2 (ja) | ||
JP2866134B2 (ja) | 機能性ポリペプチド | |
JPS62259596A (ja) | ハイブリツドタンパク質の精製方法 | |
JP2005536454A (ja) | 低アレルギー性シラカバ花粉主要アレルゲンrBetv1の製造方法 | |
JP2657861B2 (ja) | ダニ主要アレルゲンの製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005505971 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10555883 Country of ref document: US Ref document number: 2004727416 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004727416 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10555883 Country of ref document: US |